Lilly USA, LLC is the U.S. subsidiary of Eli Lilly, a major pharmaceutical company based in Indiana. It lobbies Congress on drug and pharmacy issues, including implementation of the Inflation Reduction Act, obesity treatment legislation, pharmaceutical tariffs, and drug safety and supply-chain topics. The filings show it spent about $360,000 and used the law firm Brownstein Hyatt Farber Schreck.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
ADAM STEINMETZ
The latest disclosures for this client.
BROWNSTEIN HYATT FARBER SCHRECK, LLP
Q2BROWNSTEIN HYATT FARBER SCHRECK, LLP
Q4The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
BROWNSTEIN HYATT FARBER SCHRECK, LLP
BRANDT ANDERSON
BROWNSTEIN HYATT FARBER SCHRECK, LLP
DEEMA TARAZI
BROWNSTEIN HYATT FARBER SCHRECK, LLP
EMILY FELDER
BROWNSTEIN HYATT FARBER SCHRECK, LLP
ZACHARY PFISTER
BROWNSTEIN HYATT FARBER SCHRECK, LLP
GREGORY SUNSTRUM
BROWNSTEIN HYATT FARBER SCHRECK, LLP
STEPHEN HOLLAND
BROWNSTEIN HYATT FARBER SCHRECK, LLP
BRIAN THOMAS MCGUIRE
BROWNSTEIN HYATT FARBER SCHRECK, LLP
BROWNSTEIN HYATT FARBER SCHRECK, LLP
Q3BROWNSTEIN HYATT FARBER SCHRECK, LLP
Q2BROWNSTEIN HYATT FARBER SCHRECK, LLP
Q1